A5035863074- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- AI in cancer detection
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Global Cancer Incidence and Screening
- Cancer Risks and Factors
- COVID-19 and healthcare impacts
- Healthcare cost, quality, practices
- Systemic Sclerosis and Related Diseases
- Lymphatic System and Diseases
- Blood groups and transfusion
- Healthcare Systems and Challenges
- Cancer Cells and Metastasis
- Advances in Oncology and Radiotherapy
- BRCA gene mutations in cancer
- Hematopoietic Stem Cell Transplantation
- Blood transfusion and management
- Breast Implant and Reconstruction
King's College London
2021-2024
Guy's and St Thomas' NHS Foundation Trust
2020-2024
Breast Cancer Now
2021
Abstract Background Using an updated dataset with more patients and extended follow-up, we further established cancer patient characteristics associated COVID-19 death. Methods Data on all a positive reverse transcription-polymerase chain reaction swab for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Guy’s Cancer Centre King’s College Hospital between 29 February 31 July 2020 was used. Cox proportional hazards regression performed to identify which factors were mortality....
To examine the association between size and margin status of ductal carcinoma in situ (DCIS) risk developing ipsilateral invasive breast cancer DCIS after treatment, stage subtype cancer.Multinational, pooled cohort study.Four large international cohorts.Patient level data on 47 695 women with a diagnosis pure, primary 1999 2017 Netherlands, UK, US who underwent surgery, either conserving or mastectomy, often followed by radiotherapy endocrine both.The main outcomes were 10 year cumulative...
Aims Over 50% of breast cancer cases are “Human epidermal growth factor receptor 2 (HER2) low (BC)”, characterized by HER2 immunohistochemistry (IHC) scores 1+ or 2+ alongside no amplification on fluorescence in situ hybridization (FISH) testing. The development new anti‐HER2 antibody‐drug conjugates (ADCs) for treating HER2‐low cancers illustrates the importance accurately assessing status, particularly cancer. In this study we evaluated performance a deep‐learning (DL) model assessment...
Ductal carcinoma in situ (DCIS) is widely accepted as a precursor of invasive ductal (IDC). Lobular (LCIS) considered risk factor for lobular (ILC), and it unclear whether LCIS also precursor. Therefore, would be expected that similar factors predispose to both DCIS IDC, but not necessarily ILC. This study examined associations with using data from 3075 cases, 338 1584 controls aged 35–60, recruited the UK-based GLACIER ICICLE case-control studies between 2007 2012. Analysis showed...
Invasive lobular breast cancer (ILC) accounts for 10–15% of cancers and has distinct characteristics compared with the more common invasive ductal carcinoma (IDC). Studies have shown that ILC may be less sensitive to chemotherapy than IDC, lower rates complete pathological response after neo-adjuvant chemotherapy, but it is not clear how this affects long-term survival. Patients at Guy’s St Thomas’ NHS Foundation Trust between 1975 2016 diagnosed ER+ IDC or were eligible inclusion....
Abstract Introduction Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. Considering the results DESTINY-Breast trials confirming remarkable efficacy anti-HER2 antibody drug-conjugate (T-Dxd) both HER2-overexpressed and HER2-low tumors, it necessary to identify not only (immunohistochemistry (IHC) score 3+) overexpressing but also tumors. The latter category, defined as IHC1+ or IHC2+...
Abstract Introduction Over 50% of breast cancer cases are "Human epidermal growth factor receptor 2 (HER2) low (BC)", characterized by HER2 immunohistochemistry (IHC) scores 1+ or 2+ alongside no amplification on fluorescence in situ hybridization (FISH) testing. The development new anti-HER2 antibody-drug conjugates (ADCs) for treating HER2-low cancers illustrates the importance accurately assessing status, particularly cancer. In this study, we evaluated performance a deep learning (DL)...
Abstract Clinico-pathological co-variates define a predictive model of breast cancer related lymphoedema (BCRL) in patients undergoing axillary surgery for CC Tang1*, J Timbres2*, KWD Ramsey1, A Mera2, S Irshad2, E Sawyer2, AA Khan1 1 Department Plastic Surgery, The Royal Marsden Hospital, London, UK 2 School Cancer and Pharmaceutical Sciences, Faculty Life Sciences Medicine, Guy’s Centre, King’s College UK. *These authors contributed equally Introduction Breast cancer-related negatively...
Abstract Background: The PRECISION (PREvent ductal Carcinoma In Situ Invasive Overtreatment Now) CRUK Grand Challenge project focusses on discriminating hazardous from indolent carcinoma in situ (DCIS). Aim of these analyses is to identify factors associated with a lower or higher risk developing invasive breast cancer after an initial DCIS diagnosis. Knowledge crucial our quest reducing overtreatment for women DCIS. Many clinicopathological features are hypothesized be important affecting...
Abstract Background: Although DCIS is a precursor of invasive breast cancer (IBC), most lesions never will progress. As we cannot distinguish reliably progressive from harmless yet, almost all women with are treated extensively surgery and often adjuvant radiotherapy or endocrine treatment, implying overtreatment many thousands DCIS. PRECISION aims to reduce such by identifying factors associated subsequent ipsilateral IBC. Many have been implicated in IBC risk, but studies relied on small...
Abstract Introduction Invasive lobular breast cancer (ILC) accounts for 10-15% of all invasive carcinomas and has distinct clinical biological characteristics compared with the more common ductal carcinoma (IDC). They are generally ER-positive (ER+) exception a small number pleomorphic cases there is some evidence that 10-year survival rate women ILC lower than ER+ IDC. Furthermore, studies have shown may be less sensitive to chemotherapy IDC, rates complete pathological response after...
Abstract Introduction Breast cancer is the most common malignancy affecting women under age of 35 and young at diagnosis associated with a poor prognosis. Previous studies have shown that these patients adverse tumour biology including high grade morphology, lymph node involvement lack hormone receptor expression. The aim this study was to assess outcomes risk factors different subtypes breast as defined by status in cohort central London centre. Methods Women diagnosed or younger between...